Bridgepoint, via Bridgepoint Europe VII (BE VII), a fund focused on investing in mid-market growth businesses, is to acquire RoC Skincare (RoC), with existing backer Gryphon Investors, selling its majority shareholding in RoC as part of the transaction.
Financial terms of the deal, which is expected to close in February, have not been disclosed.
RoC was founded in Paris in 1957 by Dr Jean-Charles Lissarrague and offers skin health solutions with a focus on ageing skin.
Since Gryphon Investors acquired RoC from Johnson & Johnson and established it as an independent business in 2020, the company has experienced significant organic growth, with revenue increasing by 70%. Bridgepoint plans to support RoC in further accelerating its growth in its heritage European markets and in France in particular.
The transaction represents the sixth acquisition by BE VII.
Bridgepoint was advised by Jefferies (M&A Advisor), Latham & Watkins (Legal Advisor), BCG (Commercial), EY (Financial and Tax Due Diligence), ERM (ESG Due Diligence) and Marsh (Insurance Due Diligence).
RoC was advised by Raymond James (M&A Advisor), Kirkland & Ellis (Legal Advisor) and PWC (Financial and Tax Due Diligence).
